Drug
Levomilnacipran clinical trials
Also written Fetzima and F2695.
- studies test it
- 18
- open now
- 0
- in phase 3
- 11
- first study started
- 2009
How studies write it
Studies that test it under each name
Studies by the year they started
18 studies that test it; most in 2009 (4)
| Year | Studies |
|---|---|
| 2009 | 4 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 2 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 1
- Phase 3
- 11
- Phase 4
- 4
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 5
Forest Laboratories (9) · Pierre Fabre Medicament (2) · Zhejiang Huahai Pharmaceutical Co., Ltd. (1) · Howard Aizenstein (1) · University of Minnesota (1) · Allergan (1) · University of California, Los Angeles (1) · Duke University (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Levomilnacipran is read from its arms, and is right about nine times in ten.
Testing it · 18
- Efficacy and Safety Study of Levomilnacipran Hydrochloride Extended-Release Capsules in Major Depressive DisorderCompletedPhase 3Zhejiang Huahai Pharmaceutical Co., Ltd.NCT07253207Written as Levomilnacipran Hydrochloride Extended-Release Capsules
- Neural Mechanisms of Monoaminergic Engagement in Late-life Depression Treatment Response (NEMO)CompletedPhase 4Howard AizensteinNCT03128021Written as Levomilnacipran Pill
- Novel Medication as a Potential Smoking Cessation AidCompletedNot applicableUniversity of MinnesotaNCT02265367Written as Levomilnacipran
- Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric Patients (7-17 Years) With Major Depressive DisorderCompletedPhase 3AllerganNCT03569475Written as Levomilnacipran ER
- Levomilnacipran in Healthy MalesStatus unknownPhase 4University of OttawaNCT03249311Written as Levomilnacipran
- Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive DisorderCompletedPhase 3Forest LaboratoriesNCT02431806Written as Levomilnacipran
- Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive DisorderCompletedPhase 3Forest LaboratoriesNCT01085812Written as Levomilnacipran ER
- Trial of Levomilnacipran in Geriatric DepressionCompletedPhase 4University of California, Los AngelesNCT02466958Written as levomilnacipran
- Levomilnacipran ER vs. Adjunctive Quetiapine for Adults With Inadequate Relief With SSRIs in MDDCompletedPhase 3Duke UniversityNCT02720198Written as Levomilnacipran
- A Multicenter, Relapse Prevention Study With Levomilnacipran Extended Release (ER) in Participants With Major Depressive DisorderCompletedPhase 4Forest LaboratoriesNCT02288325Written as Levomilnacipran ER
- Effect of F2695 on Brain Activity Measured by Functional Magnetic Resonance ImagingCompletedPhase 1Pierre Fabre MedicamentNCT02266966Written as F2695
- Effect of F2695 on Functional Recovery After Ischemic StrokeCompletedPhase 3Pierre Fabre MedicamentNCT01639014Written as F2695
- Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive DisorderCompletedPhase 2Forest LaboratoriesNCT01254305Written as Levomilnacipran ER
- Safety and Efficacy of Levomilnacipran ER (Levomilnacipran SR) in Major Depressive DisorderCompletedPhase 3Forest LaboratoriesNCT01377194Written as Levomilnacipran ER
- Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive DisorderCompletedPhase 3Forest LaboratoriesNCT01034462Written as Levomilnacipran ER
- Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive DisorderCompletedPhase 3Forest LaboratoriesNCT00969150Written as Levomilnacipran ER
- Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive DisorderCompletedPhase 3Forest LaboratoriesNCT00969709Written as Levomilnacipran ER
- Safety Study of F2695 SR in Major Depressive DisorderCompletedPhase 3Forest LaboratoriesNCT01034267Written as F2695 SR
Codes
What other systems call Levomilnacipran · ClinicalTrials.gg INT006837
- MeSH (NLM) D000078862LevomilnacipranConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) UGM0326TXXLEVOMILNACIPRANConfirmed FDA, NLM, Wikidata
- RxNorm 1433212Confirmed FDA, Wikidata
- Wikidata Q6535779levomilnacipranConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C170117LevomilnacipranOne source FDA
- DrugBank DB08918One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000078862 | Levomilnacipran | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | UGM0326TXX | LEVOMILNACIPRAN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1433212 | — | Confirmed FDA, Wikidata |
| Wikidata | Q6535779 | levomilnacipran | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C170117 | Levomilnacipran | One source FDA |
| DrugBank | DB08918 | — | One source Wikidata |
Also registered as levomilnacipran hydrochloride (UNII 371U2ZK31U · RxNorm 1433211).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.